

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHMITT et al.

Atty. Dck. No. 100564-00082

Serial No.: New PCT Application

Filed: April 13, 2000

For: DIAGNOSTIC AND THERAPEUTIC USE OF ANTIBODIES AGAINST THE UROKINASE RECEPTOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231
Sir:


Date: October 15, 2001

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
 - ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☒ 4. The reference was cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully submitted,


Robert B. Murray
Registration No. 22,980

Customer No. 004372
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810
RBM/baw

09/926323

Sheet 1 of 3

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100564-00082	New PCT Application
LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANTS Manfred SCHMITT; Frank NOACK; Viktor MAGDOLEN; Henner GRAEFF; Thomas LUTHER; Sybille ALBRECHT; Martin MULLER; Olaf WILHELM AND Nadia HARBECK	
		FILING DATE April 13, 2000	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	US 5 234 816 A (TERSTAPPEN LEON W M M)	10 August 1993 (1993-08-10)	(TERSTAPPEN LEON W M M) the whole document			
	AB	EP 0 317 156 A (BECTON DICKINSON CO)	24 May 1989 (1989-05-24)	Claims 1-10			
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	W. XUE ET AL.: "Urokinase-type plasminogen activator receptors associate with betal and beta 3 integrins of fibrosarcoma cells: dependence on extracellular matrix components: CANCER RESEARCH Vol. 57, no. 9, 1 May 1997 (1997i-05-01), pages 1682-1689, XP002117246 Baltimore, MD, VSA abstract; figure 1
AN	T. LUTHER ET AL.: "Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue" AMERICAN JOURNAL OF PATHOLOGY, vol. 150, no. 4, April 1997 (1997-04), Pages 1231-1244, XP002117251 Hagerstown, MD, VSA cited in the whole document

	AO	R. TODD ET AL.: "CD87 Workshop Panel report (pages 1016-1020 in 'Leucocyte Typing VI', Eds. T. Kishimoto et al.)" 1997, GARLAND PUBLISHING, INC. XP002117252 Cited in the application figures tables
--	----	---

	AP	V. MAGDOLEN ET AL.: "Epitope-mapped monoclonal antibodies directed to the human urokinase receptor (uPAR, CD87)." TISSUE ANTIGENS, vol. 48, no. 4-2, October 1996 (1996-10), page 424 XP000929590 Kopenhagen, Dänemark Abstract MC-2-02
--	----	--

	AQ	K. FISCHER ET AL.: "Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function." FEBS LETTERS, vol. 438, no. 1-2, 30 October 1998 (1998-10-30), pages 101-105, XP002143814 Amsterdam, die Nederland Abstract figure 3
--	----	--

	AU	H. ALLGAYER ET AL.: "Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA and receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol" JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 45, no. 2, February 1997 (1997-02), Baltimore, MD, USA cited in the application abstract
--	----	--

	AR	M. HEISS ET AL.: "individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer" NATURE MEDICINE, vol. 1, no. 10, October 1995 (1995-10), pages 1035-1039, XP02117248 New York, NY, USA cited in the application page 1039, column 1, line 18, paragraph 2 - line 39
--	----	--

	AS	I. FUNKE ET AL.: "comparative analyses of bone marrow micrometastases in breast and gastric cancer" INTERNATIONAL JOURNAL OF CANCER, vol. 65, no. 6, 15 March 1996 (1996-03-15), pages 755-761, XP002117249 New York, NY, USA cited in the application abstract.
--	----	--

	AT	R. CICCOCIOPPO ET AL.: "Detection of the receptor for the human urokinase-type fluoresceinated uPA" JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 45, no. 9, September 1997 (1997-09), Baltimore, MD, USA cited in the application figures 1, 2
--	----	---

09/926323

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

RBM/baw